Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Status:
TERMINATED
Trial end date:
2025-09-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.